Skip to main content Accessibility help

Polymorphisms in genes within the IGF-axis influence antenatal and postnatal growth

  • P. G. Parmar (a1), J. A. Marsh (a1), H. Rob Taal (a2) (a3) (a4), M. Kowgier (a5) (a6), A. G. Uitterlinden (a3) (a7), F. Rivadeneira (a3) (a7), L. Briollais (a5), J. P. Newnham (a1), A. Hofman (a3), S. J. Lye (a5), E. A. P. Steegers (a8), C. M. van Duijn (a3), L. J. Palmer (a5) (a6), V. W. V. Jaddoe (a2) (a3) (a4) and C. E. Pennell (a1)...


Two pregnancy cohorts were used to investigate the association between single-nucleotide polymorphisms (SNPs) in genes within the insulin-like growth factor (IGF)-axis and antenatal and postnatal growth from birth to adolescence. Longitudinal analyses were conducted in the Raine pregnancy cohort (n = 1162) using repeated measures of fetal head circumference (HC), abdominal circumference (AC) and femur length (FL) from 18 to 38 weeks gestation and eight measures of postnatal height and weight (1–17 years). Replications of significant associations up to birth were undertaken in the Generation R Study (n = 2642). Of the SNPs within the IGF-axis genes, 40% (n = 58) were associated with measures of antenatal growth (P ⩽ 0.05). The majority of these SNPs were in receptors; IGF-1R (23%; n = 34) and IGF-2R (13%; n = 9). Fifteen SNPs were associated with antenatal growth (either AC or HC or FL) in Raine (P ⩽ 0.005): five of which remained significant after adjusting for multiple testing. Four of these replicated in Generation R. Associations were identified between 38% (n = 55) of the IGF-axis SNPs and postnatal height and weight; 21% in IGF-1R (n = 31) and 9% in IGF-2R (n = 13). Twenty-six SNPs were significantly associated with both antenatal and postnatal growth; 17 with discordant effects and nine with concordant effects. Genetic variants in the IGF-axis appear to play a significant role in antenatal and postnatal growth. Further replication and new analytic methods are required in order to better understand this key metabolic pathway integrating biologic knowledge about the interaction between IGF-axis components.


Corresponding author

*Address for correspondence: C. E. Pennell, MBBS, PhD, School of Women's and Infants' Health, The University of Western Australia, 35 Stirling Hwy, Crawley WA 6009 Australia, UWA Mail Box: M550. (Email


Hide All
1.Le Roith, D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997; 336, 633640.
2.Monzavi, R, Cohen, P. IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab. 2002; 16, 443447.
3.Rajaram, S, Baylink, DJ, Mohan, S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997; 18, 801831.
4.Rother, KI, Accili, D. Role of insulin receptors and IGF receptors in growth and development. Pediatr Nephrol. 2000; 14, 558561.
5.Delafontaine, P, Song, YH, Li, Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004; 24, 435444.
6.Kim, H-S, Rosenfeld, RG, Oh, Y. Biological roles of insulin-like growth factor binding proteins (IGFBPs). Exp Mol Med. 1997; 29, 8596.
7.Wolf, E, Lahm, H, Wu, M, Wanke, R, Hoeflich, A. Effects of IGFBP-2 overexpression in vitro and in vivo. Pediatr Nephrol. 2000; 14, 572578.
8.Ahmad, I, Beharry, KDA, Valencia, AM, et al. Influence of a single course of antenatal betamethasone on the maternal-fetal insulin-IGF-GH axis in singleton pregnancies. Growth Horm IGF Res. 2006; 16, 267275.
9.Gohlke, BC, Fahnenstich, H, Dame, C, Albers, N. Longitudinal data for intrauterine levels of fetal IGF-I and IGF-II. Horm Res. 2004; 61, 200204.
10.Gohlke, BC, Huber, A, Hecher, K, et al. Fetal insulin-like growth factor (IGF)-I, IGF-II, and ghrelin in association with birth weight and postnatal growth in monozygotic twins with discordant growth. J Clin Endocrinol Metab. 2005; 90, 22702274.
11.Lassare, C, Hardouin, S, Daffos, F, et al. Serum insulin-like growth factor and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res. 1991; 29, 219225.
12.Reece, EA, Wiznittzer, A, Le, E, et al. The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol. 1994; 84, 8895.
13.Westwood, M. Role of insulin-like growth factor binding protein 1 in human pregnancy. Rev Reprod. 1999; 4, 160167.
14.Le Roith, D, Werner, H, Beitner-Johnson, D, Roberts, CT. The IGF System: Molecular Biology, Physiology and Clinical Applications, 1999. Humana Press, Inc.: Totowa, NJ, USA.
15.Smith, GD, Gunnell, D, Holly, J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ. 2000; 321, 847848.
16.Constancia, M, Hemberger, M, Hughes, J, et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature. 2002; 417, 945948.
17.Robertson, EJ. Insulin-like growth factors, imprinting and embryonic growth control. Dev Biol. 1995; 6, 293299.
18.Sara, VR, Hall, K. Insulin-like growth factors and their binding proteins. Physiol Rev. 1990; 70, 591614.
19.Firth, SM, Baxter, RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23, 824854.
20.Salih, DA, Tripathi, G, Holding, C, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci U S A. 2004; 101, 43144319.
21.Williams, LA, Evans, SF, Newnham, JP. Prospective cohort study of factors influencing the relative weights of the placenta and the newborn infant. BMJ. 1997; 314, 18641868.
22.Newnham, JP, Evans, SF, Michael, CA, Stanley, FJ, Landau, LI. Effects of frequent ultrasound during pregnancy: a randomised controlled trial. Lancet. 1993; 342, 887891.
23.Jaddoe, V, Bakker, R, van Duijn, C. The Generation R Study Biobank: a resource for epidemiological studies in children and their parents. Eur J Epidemiol. 2007; 22, 917923.
24.Jaddoe, VW, van Duijn, CM, van der Heijden, AJ, et al. The Generation R Study: design and cohort update 2010. Eur J Epidemiol. 2010; 25, 823841.
25.Mook-Kanamori, DO, Marsh, JA, Warrington, NM, et al. Variants near CCNL1/LEKR1 and in ADCY5 and fetal growth characteristics in different trimesters. J Clin Endocrinol Metab. 2011; 96, E810E815.
26.Carter, KW, McCaskie, PA, Palmer, LJ. SimHap GUI: an intuitive graphical user interface for genetic association analysis. BMC Bioinform. 2008; 9, 557.
27.Laird, NM, Ware, JH. Random-effects models for longitudinal data. Biometrics. 1982; 38, 963974.
28.R: A Language and Environment for Statistical Computing [computer program], 2009, Vienna, Austria: R Foundation for Statistical Computing, URL
29.Gao, X, Starmer, J, Martin, ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008; 32, 361369.
30.Massague, J, Czech, MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 1982; 257, 50385045.
31.Jones, IJ, Clemmons, DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16, 334.
32.Rechler, MM. Insulin-like growth factor binding proteins. Vitam Horm. 1993; 47, 1114.
33.Barker, DJ. The fetal origins of adult hypertension. J Hypertens Suppl. 1992; 10, S39S44.
34.Barker, DJ. Intrauterine programming of coronary heart disease and stroke. Acta Paediatr Suppl. 1997; 423, 178182; discussion 183.
35.Barker, DJ. The developmental origins of chronic adult disease. Acta Paediatr Suppl. 2004; 93, 2633.
36.Barker, DJ. The developmental origins of insulin resistance. Horm Res. 2005; 64(Suppl. 3), 27.
37.Barker, DJ. The origins of the developmental origins theory. J Intern Med. 2007; 261, 412417.
38.Barker, DJ, Osmond, C, Golding, J, Kuh, D, Wadsworth, ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989; 298, 564567.
39.Newnham, JP, Pennell, CE, Lye, SJ, Rampono, J, Challis, JR. Early life origins of obesity. Obstet Gynecol Clin North Am. 2009; 36, 227244, xii.
40.Abuzzahab, MJ, Schneider, A, Goddard, A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003; 349, 22112222.
41.Callan, AC, Milne, E. Involvement of the IGF system in fetal growth and childhood cancer: an overview of potential mechanisms. Cancer Causes Control. 2009; 20, 17831798.
42.Frayling, TM, Hattersley, AT, McCarthy, A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes. 2002; 51, 23132316.
43.Mohan, S, Amarnani, S, Baylink, DJ. Insulin-like growth factors and their binding proteins: role in pre- and postnatal growth and development. Inland Pediatr. 1991; 6, 17.
44.Pirazzoli, P, Cacciari, E, De Iasio, R, et al. Developmental pattern of fetal growth hormone, insulin-like growth factor I, growth hormone binding protein and insulin-like growth factor binding protein-3. Arch Dis Child Fetal Neonatal Ed. 1997; 77, F100F104.
45.Freathy, RM, Mook-Kanamori, DO, Sovio, U, et al. Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet. 2010; 42, 430435.
46.Hattersley, AT, Tooke, JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet. 1999; 353, 17891792.
47.Weng, L, Macciardi, F, Subramanian, A, et al. SNP-based pathway enrichment analysis for genome-wide association studies. BMC Bioinform. 2011; 12, 99.
48.Peng, G, Luo, L, Siu, H, et al. Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet. 2010; 18, 111117.
49.Tisi, DK, Liu, X, Wykes, LJ, Skinner, CD, Koskl, KG. Insulin-like growth factor II and binding proteins 1 and 3 from second trimester human amniotic fluid are associated with infant birth weight. J Nutr. 2005; 135, 16671672.
50.El-Shewy, HM, Luttrell, LM. Insulin-like growth factor-2/mannose-6 phosphate receptors. Vitam Horm. 2009; 80, 667697.
51.Kalus, W, Zweckstetter, M, Renner, C, et al. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. 1998; 17, 65586572.
52.Neumann, GM, Marinaro, JA, Bach, LA. Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6. Biochemistry. 1998; 37, 65726585.
53.Carrick, FE, Forbes, BE, Wallace, JC. BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J Biol Chem. 2001; 276, 2712027128.
54.Galanis, M, Firth, SM, Bond, J, et al. Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. J Endocrinol. 2001; 169, 123133.
55.Siwanowicz, I, Popowicz, GM, Wisniewska, M, et al. Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure. 2005; 13, 155167.
56.Forbes, BE, McCarthy, P, Norton, RS. Insulin-like growth factor binding proteins: a structural perspective. Front Endocrinol (Lausanne). 2012; 3, 113.
57.Busby, WH Jr, Klapper, DG, Clemmons, DR. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions. J Biol Chem. 1988; 263, 1420314210.
58.Yu, J, Iwashita, M, Kudo, Y, Takeda, Y. Phosphorylated insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1 stimulates IGF-I-induced amino acid uptake by cultured trophoblast cells. Growth Horm IGF Res. 1998; 8, 6570.
59.Hoflich, A, Lahm, H, Blum, W, Kolb, H, Wolf, E. Insulin-like growth factor-binding proteins-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett. 1998; 434, 329334.
60.Mohseni-Zadeh, S, Binoux, M. Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology. 1997; 138, 56455648.


Type Description Title
Supplementary materials

PARMAR Supplementary Material

 Word (505 KB)
505 KB

Polymorphisms in genes within the IGF-axis influence antenatal and postnatal growth

  • P. G. Parmar (a1), J. A. Marsh (a1), H. Rob Taal (a2) (a3) (a4), M. Kowgier (a5) (a6), A. G. Uitterlinden (a3) (a7), F. Rivadeneira (a3) (a7), L. Briollais (a5), J. P. Newnham (a1), A. Hofman (a3), S. J. Lye (a5), E. A. P. Steegers (a8), C. M. van Duijn (a3), L. J. Palmer (a5) (a6), V. W. V. Jaddoe (a2) (a3) (a4) and C. E. Pennell (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed